H
Himal Amin
Researcher at Janssen Pharmaceutica
Publications - 21
Citations - 1793
Himal Amin is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Daratumumab & Bortezomib. The author has an hindex of 9, co-authored 18 publications receiving 1289 citations.
Papers
More filters
Journal ArticleDOI
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo,Asher Chanan-Khan,Katja Weisel,Ajay K. Nooka,Tamás Masszi,Meral Beksac,Ivan Spicka,Vania Hungria,Markus Munder,Maria-Victoria Mateos,Tomer M Mark,Ming Qi,Jordan M. Schecter,Himal Amin,Xiang Qin,William Deraedt,Tahamtan Ahmadi,Andrew Spencer,Pieter Sonneveld +18 more
TL;DR: Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than borteonib and DexamethAsone alone and was associated with infusion-related reactions and higher rates of thrombocytopenia and neutropenia.
Journal ArticleDOI
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
Andrew Spencer,Suzanne Lentzsch,Katja Weisel,Hervé Avet-Loiseau,Tomer M Mark,Ivan Spicka,Tamás Masszi,Birgitta Lauri,Mark-David Levin,Alberto Bosi,Vania Hungria,Michele Cavo,Je-Jung Lee,Ajay K. Nooka,Hang Quach,Cindy Lee,Wolney Barreto,Paolo Corradini,Chang-Ki Min,Emma C. Scott,Asher Chanan-Khan,Noemi Horvath,Marcelo Capra,Meral Beksac,Roberto Ovilla,Jae Cheol Jo,Ho Jin Shin,Pieter Sonneveld,David Soong,Tineke Casneuf,Christopher Chiu,Himal Amin,Ming Qi,Piruntha Thiyagarajah,A. Kate Sasser,Jordan M. Schecter,Maria-Victoria Mateos +36 more
TL;DR: Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse.
Journal ArticleDOI
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos,Evangelos Terpos,Mario Boccadoro,Sosana Delimpasi,Meral Beksac,Eirini Katodritou,Philippe Moreau,Luca Baldini,Argiris Symeonidis,Jelena Bila,Albert Oriol,Maria-Victoria Mateos,Hermann Einsele,Ioannis Orfanidis,Tahamtan Ahmadi,Jon Ukropec,Tobias Kampfenkel,Jordan M. Schecter,Yanping Qiu,Himal Amin,Jessica Vermeulen,Robin Carson,Pieter Sonneveld,Adrian Alegre Amor,Angelo Belotti,Lotfi Benboubker,Britta Besemer,Sevgi Besisik,Michele Cavo,Javier De La Rubia Comos,Chantal Doyen,Dominik Dytfeld,Monika Engelhardt,Thierry Facon,Roberto Foà,Hartmut Goldschmidt,Sebastian Grosicki,Roman Hájek,Guner Hayri Ozsan,Cyrille Hulin,Brian Iversen,Lionel Karlin,Stefan Knop,Marie-Christine Kyrtsonis,Juan José Lahuerta,Xavier Leleu,Carmen Martinez Chamorro,María-Victoria Mateos Manteca,Nathalie Meuleman,Monique C. Minnema,Massino Offidani,Albert Oriol Rocafiguera,Mustafa Pehlivan,Ludek Pour,Henk Th.J. Roerdink,Laura Rosinol Dacsh,Hans Salwender,Anargyros Symeonidis,Charlotte Toftmann Hansen,Tulin Tuglular,Ali Unal,Philip Vlummens,Filiz Vural,Ka Lung Wu,Sonja Zweegman +64 more
TL;DR: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma as discussed by the authors.
Journal ArticleDOI
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Maria-Victoria Mateos,Pieter Sonneveld,Vania Hungria,Ajay K. Nooka,Jane Estell,Wolney Barreto,Paolo Corradini,Chang-Ki Min,Eva Medvedova,Katja Weisel,Christopher Chiu,Jordan M. Schecter,Himal Amin,Xiang Qin,Jon Ukropec,Rachel Kobos,Andrew Spencer +16 more
TL;DR: After 3 years, D-Vd maintained significant benefits in patients with relapsed or refractory multiple myeloma with a consistent safety profile and provided the greatest benefit at first relapse and increased MRD-negativity rates.
Journal ArticleDOI
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Hervé Avet-Loiseau,Jesús F. San-Miguel,Tineke Casneuf,Shinsuke Iida,Sagar Lonial,Saad Z. Usmani,Andrew Spencer,Philippe Moreau,Torben Plesner,Katja Weisel,Jon Ukropec,Christopher Chiu,Sonali Trivedi,Himal Amin,Maria Krevvata,Priya Ramaswami,Xiang Qin,M. Qi,Steven Sun,Ming Qi,Rachel Kobos,Nizar J. Bahlis +21 more
TL;DR: In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX and CASTOR.